IDP Pharma announces first patient dosed in a Phase 1/ 2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader

IDP Pharma United States of America Spain

IDP-121 is IDP Pharma's lead asset using its proprietary intrametics™ technology platform enabling inhibition and cellular degradation of intrinsically disordered proteins (IDPs)Targeting cMyc, a pivotal protein in tumorigenesis, is a unique opportunity in cancer therapyFirst patient successfully dosed in clinical Phase I/II dose escalation and expansion study in relapsed/refractory hematological malignancies(Identifier: NCT05908409).

About IDP-121

IDP-121 is a potent, selective peptidomimetic that acts by simultaneously obstructing the formation of the cMyc/Max complex while also augmenting cMyc degradation through the intrinsic cellular machinery. This effectively counters the oncogenic impact of elevated cMyc protein levels that fuel the proliferation of cancer cells. Preclinical investigations of IDP-121 have revealed strong anti-tumor efficacy across various hematological and solid tumors, including multiple myeloma, non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). IDP-121-001 (CASSANDRA) is the first clinical study involving IDP-121. Planned future clinical trials will include exploration in solid tumors and in combination with standard of care therapies.

About IDP Pharma

IDP Pharma is a clinical-stage biotech company developing the first direct inhibitors and degraders of intrinsically disordered proteins (IDPs), a novel class of disease drivers previously considered undruggable. Thanks to its proprietary intrameticstm platform, the company has successfully developed a pipeline of first in class drugs targeting IDPs, leading the field since its foundation. The company is headquartered in Parc Científic de Barcelona (PCB), in Barcelona, Spain.

More information please visit www.idp-pharma.com

Forward-looking statements

The forward-looking statements made in this press release relate only to the events or information as of the date on which the statements are made in this article. You should read this article completely and with the understanding that actual future results with IDP-121 may be materially different from what we expect. Statements contained in this press release are made as of the date of this document and any further interpretation may change considering future developments.

Logo: https://mma.prnewswire.com/media/2257838/IDP_Pharma_Logo.jpg

For further inquiries please contact:
IDP Pharma
Santiago Esteban, Ph.D., Chief Executive Officer
E-mail: [e-mail]

LifeSpring Life Sciences Communication, Amsterdam
Léon Melens
Tel: [phone]
E-mail: [e-mail]

View original content:https://www.prnewswire.co.uk/news-releases/idp-pharma-announces-first-patient-dosed-in-a-phase-12-clinical-trial-of-idp-121-a-direct-cmyc-protein-inhibitor-and-degrader-301967925.html